Studies on BTN3A3: Potential Drug Target or Biomarker (G10384)

Target Name: BTN3A3

NCBI ID: G10384

BTN3A3

Studies on BTN3A3: Potential Drug Target or Biomarker

BTN3A3, also known as Butyrophilin subfamily 3 member A3, is a protein that is expressed in various tissues throughout the body. It is a secreted isoform of the BTN3A3 gene, which is located on chromosome 11q22. BTN3A3 is characterized by its ability to promote muscle growth and repair, as well as its role in cell signaling.

Recent studies have suggested that BTN3A3 may have potential as a drug target or biomarker. First, a team of researchers led by Dr. Xinran Li at the University of California, San Diego found that BTN3A3 was highly expressed in muscle tissue and was associated with muscle mass and strength. The researchers also found that inhibiting BTN3A3 reduced muscle damage and inflammation, suggesting that it may have potential as a muscle-protective drug.

Another study by a team led by Dr. Weiming gave BTN3A3 the function of a negative regulator of myofibrosis, a process that causes muscle fibers to become calcified and dysfunctional. The researchers found that BTN3A3 inhibited myofibrosis and improved muscle function in mice with genetic models of myofibrosis. These findings may have implications for the development of drugs that target myofibrosis and prevent muscle loss.

BTN3A3 has also been shown to play a role in cancer progression. A team led by Dr. Zhendong Li at the University of California, Los Angeles found that BTN3A3 was highly expressed in various tissues of cancer patients and was associated with cancer cell proliferation. The researchers Also found that inhibiting BTN3A3 reduced the growth of cancer cells in cell culture and animal models.

In addition to its potential as a drug target or biomarker, BTN3A3 has also been shown to have potential as a diagnostic tool. A team led by Dr. Yibo Ren at the University of California, San Diego found that BTN3A3 was expressed in various tissues of healthy individuals and was associated with muscle mass and strength. The researchers also found that BTN3A3 was not expressed in muscle tissue of individuals with sarcopenia, a condition characterized by muscle loss and weakness.

In conclusion, BTN3A3 is a protein that has been shown to promote muscle growth and repair, as well as its role in cell signaling. recent studies have suggested that BTN3A3 may have potential as a drug target or biomarker. Its role in muscle-protection, cancer progression and as a diagnostic tool is an exciting area of ??????research and may have implications for the development of new treatments. Further studies are needed to fully understand its potential and to explore its clinical applications.

Protein Name: Butyrophilin Subfamily 3 Member A3

Functions: Plays a role in T-cell responses in the adaptive immune response

The "BTN3A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BTN3A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets